Bicara Therapeutics Inc.

Bicara Therapeutics Inc. announced it awarded inducement grants on July 1, 2026, to four new employees. These grants consisted of non-qualified stock options to purchase an aggregate of 191,425 shares of common stock, with an exercise price of $28.91 per share. The options vest over time, with one-fourth vesting on the first anniversary of the start date and the remainder in 12 equal quarterly installments, subject to continued service. The awards were made under Bicara's 2026 Inducement Plan, approved by the board's compensation committee.

Bicara Therapeutics announced positive three-year follow-up data from its Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic HPV-negative HNSCC. The 1500mg weekly dose demonstrated an estimated 31% overall survival at three years, approximately doubling the survival rate compared to standard of care. The data showed deep, durable responses driven by TGF-β inhibition and a well-tolerated safety profile, reinforcing its potential as a best-in-class therapy. The company is advancing to a Phase 3 study and plans a new dosing regimen study in Q3 2026.

Bicara Therapeutics reported its first quarter 2026 financial results, with a net loss of $56.2 million, up from $36.8 million in Q1 2025, driven by increased R&D and G&A expenses. The company significantly bolstered its cash position to $539.8 million, including $161.8 million from a public offering, extending its cash runway into the first half of 2029. Bicara also announced plans to initiate a new randomized clinical study for ficerafusp alfa in Q3 2026 and made key executive appointments, including a new Chief Medical Officer and Chief Commercial Officer.

Bicara Therapeutics Inc. announced it will report its first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss these updates. Interested parties can register for the call to receive dial-in details or access the live webcast via the Investors page on Bicara's website.

Bicara Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 9, 2026. Stockholders of record as of April 15, 2026, will vote on the election of two Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026. The board of directors will also be reduced from ten to nine members, as Nils Lonberg, Ph.D. will not stand for re-election.